A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Amgen Inc.

Contact Research Centre

Asthma

Not yet recruiting

Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

Registered drug

Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

Registered drug

Germany

Participants:0–17 years
Substances:Salmeterol
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:CSL Behring LLC

Contact Research Centre

Amyotrophic lateral sclerosis

Not yet recruiting

Study on the Effectiveness and Safety of Masitinib and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug

Study on the Effectiveness and Safety of Masitinib and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Masitinib
Sponsor:Ab Science

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Jena

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on multiple myeloma, prostate cancer, and gastric cancer treatments. Studies evaluating novel therapeutic combinations and targeted approaches for various cancer types.

Hematologic Malignancies
Solid Tumors
Targeted Therapies

Innovative treatments including antibody-drug conjugates and immunotherapy combinations for improved patient outcomes.

02 Cardiovascular Studies

Research investigating treatments for hypertrophic cardiomyopathy and advanced cardiovascular disease. Trials exploring new approaches to reduce major cardiovascular events and improve patient quality of life.

Heart Disease Management
Cardiovascular Risk Reduction
Novel Therapeutic Approaches

Focus on both preventive measures and treatment of established cardiovascular conditions.

03 Autoimmune Disorders

Clinical investigations of treatments for systemic lupus erythematosus, Sjögren's Disease, and other autoimmune conditions. Studies evaluating new biological therapies and targeted treatments.

Inflammatory Diseases
Immunotherapy
Disease-Modifying Treatments

Comprehensive research into improving treatment outcomes for patients with chronic autoimmune conditions.

Back to Germany All countries